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Empagliflozin. Results of the EMPA-REG 
OUTCOME trial. A breakthrough  
in treatment of type 2 diabetes?
AbsTRACT
Cardiovascular (CV) complications are the main health 
challenge among type 2 diabetic patients. They may 
cause premature death, disability and reduce the quality 
of life. Administering a multifactorial intervention aimed 
at controlling glycaemia, lipaemia and arterial blood 
pressure allows to reduce the risk of their occurrence.
FDA ruled that all newly introduced hypoglycaemic 
agents must undergo tests for CV safety. The EMPA-
REG OUTCOME trial was conducted on a  group of 
type 2 diabetic patients at high CV risk. It showed 
that including empagliflozin in the standard therapy 
reduces the risk of primary outcome (death from CV 
causes, non-fatal myocardial infarction or non-fatal 
stroke) by 14% and all-cause mortality by 32%. The 
causes of this effect of empagliflozin — an inhibitor 
of sGLT2, which is an enzyme present only in renal 
proximal tubules — are unclear. Reduction in insulin 
resistance and in oxidative stress, changes in lipid 
levels, reduction in uric acid levels, in albuminuria, in 
blood pressure and reduction in sympathetic activity 
are all named as potential mechanisms underlying the 
protective effect of empagliflozin.
Results of the EMPA-REG OUTCOME trial are a break-
through in the treatment of diabetes, and if other 
sGLT2 inhibitors are found to have similar effects, 
a fundamental change in therapy recommendations 
for this patient population may be made. (Clin Diabet 
2016; 5, 3: 107–110)
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Introduction
Cardiovascular (CV) complications are the main health 
problem among type 2 diabetic patients [1]. In this patient 
population, a concomitant CV disease multiplies the risk of 
premature death [2]. A multifactorial therapy, encompass-
ing simultaneous normalization of glycaemia, lipaemia and 
arterial blood pressure, allows to reduce this risk [3]. Data 
concerning the effect of glycaemia normalization on CV 
complications is inconsistent. On one hand, an intervention 
aimed at reducing CV risk showed no effects [4–6]. On the 
other hand, however, such preventive effect of glycaemia 
normalization was documented during a prolonged, 
20-year-long observation [7]. The effect of individual 
hypoglycaemic agents on CV safety is a separate issue 
[8]. Due to these doubts, U.S. Food and Drug Administra-
tion (FDA) ruled that all newly introduced hypoglycaemic 
agents are required to undergo tests for CV safety [9].
Flozins — sodium-glucose linked transporter 2 
(SGLT2) inhibitors — are the newest class of hypogly-
caemic agents. Their mechanism of action is based on 
blocking glucose reabsorption from the renal ultrafil-
trate and therefore inducing glycosuria [10]. Clinical 
effect of using SGLT2 inhibitors, apart from a reduction 
in HbA1c levels, manifests itself as loss of body weight 
and a slight decrease in systolic arterial blood pressure 
[11]. At the same time, using this class of drugs causes 
an increase in the levels of HDL and LDL cholesterol 
fractions, as well as adverse effects, such as urinary 
tract and genitourinary infections [12].
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Table 1. The EMPA-REG OUTCOME trial. baseline characteristics of subjects — metabolic condition
Placebo
(n = 2333)
Empagliflozin
10 mg
(n = 2345)
Empagliflozin
25 mg
(n = 2342)
HbA1c (%) 8.08 8.07 8.06
BMI [kg/m2] 30.7 30.6 30.6
Duration of diabetes ≤ 5 years [n (%)] 423 (18.1) 406 (17.3) 434 (18.6)
Duration of diabetes 5–10 years [n (%)] 571 (24.5) 585 (24.9) 590 (25.2)
Duration of diabetes > 10 years [n (%)] 1339 (57.4) 1354 (57.7) 1318 (56.3)
Systolic BP [mm Hg] 135.8 134.9 135.6
Diastolic BP [mm Hg] 76.8 76.6 76.6
LDL [mg/dL] 84.9 86.3 85.5
Table 2. The EMPA-REG OUTCOME trial. baseline characteristics of subjects — presence of cardiovascular disorders
Placebo
(n = 2333)
Empagliflozin
10 mg
(n = 2345)
Empagliflozin
25 mg
(n = 2342)
Presence of CV risk factors 2307 (98.9%) 2333 (99.5%) 2324 (99.2%)
Coronary artery disease 1763 (75.6%) 1782 (76.0%) 1763 (75.3%)
Multivessel coronary artery disease 1100 (47.1%) 1078 (46.0%) 1101 (47.0%)
Prior myocardial infarction 1083 (46.4%) 1107 (47.2%) 1083 (46.2%)
CABG 563 (24.1%) 594 (25.3%) 581 (24.8%)
Peripheral artery disease 479 (20.5%) 465 (19.8%) 517 (22.1%)
Prior stroke 553 (23.7%) 535 (22.8%) 549 (23.4%)
Heart failure 244 (10.5%) 240 (10.2%) 222 (9.5%)
Empagliflozin is one of the most recently intro-
duced drugs belonging to this class. Its clinical effects 
have been confirmed in multiple clinical trials [13–15]. 
The EMPA-REG OUTCOME trial was performed in order 
to assess CV morbidity and mortality in patients with 
type 2 diabetes at high CV risk. Its results were pre-
sented during the European Association for the Study 
of Diabetes Meeting in September 2015 and simultane-
ously published [16].
The EMPA-REG OUTCOME trial
Over 7 thousand patients with type 2 diabetes 
and a CV disease took part in the trial (Table 1 and 2). 
Exclusion criteria included patients with BMI above 
45 kg/m2, GFR below 30 mL/min/1.73 m2 or HbA1c levels 
outside of 7–10% range. All patients were administered 
unchanged hypoglycaemic therapy during 12 weeks 
preceding randomization. 
After the initial period, patients were randomly 
divided (randomized) into groups receiving either 
empagliflozin at a  dose of 10 or 25 mg or placebo 
in a 1:1:1 ratio. The drugs were added to the current 
hypoglycaemic therapy. During the trial, investigators 
were encouraged to adjust treatment of other CV risk 
factors, including hypertension and dyslipidemia.
The following were assessed during the trial:
 — occurrence of a primary outcome — death from CV 
causes, non-fatal myocardial infarction (excluding 
silent myocardial infarction) or non-fatal stroke;
 — secondary outcome additionally included hospi-
talization for unstable angina;
 —  furthermore, changes in the following parameters 
compared to baseline values were analysed: HbA1c 
levels, weight, WHR, blood pressure, heart rate, LDL 
and HDL cholesterol levels and uric acid levels.
Results
A significant reduction in the risk of all analysed 
outcomes was noticed in case of patients treated us-
ing empagliflozin (Table 3). This significant reduction 
was similar for both patients receiving 10 mg dose of 
empagliflozin and patients receiving 25 mg dose of 
empagliflozin. After 12 weeks of therapy, reduction 
in HbA1c levels achieved in the groups treated using 
empagliflozin was different compared to reduction in 
HbA1c levels achieved in the placebo group, by 0.54% 
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(10 mg dose) and 0.6% (25 mg dose). After 206 weeks 
of therapy these differences were lower: 0.24% (10 mg 
dose) and 0.36% (25 mg dose). Frequency of hypogly-
caemic events was similar in all groups; respectively, 
they affected 27.9% of patients in the placebo group, 
28% of patients in the 10 mg empagliflozin group and 
27.6% of patients in the 25 mg empagliflozin group. 
Severe hypoglycaemic events occurred in 1.5% of 
patients receiving placebo, 1.4% of patients receiving 
10 mg empagliflozin and 1.3% of patients receiving 
25 mg empagliflozin. A slight reduction in body weight, 
uricemia, blood pressure and a slight increase in the 
levels of HDL and LDL cholesterol fractions were noted 
in patients treated using empagliflozin compared to 
values observed during the placebo therapy. Analysing 
the frequency of adverse events, the authors of the trial 
found that genital infections affecting both sexes were 
significantly more common in groups receiving empa-
gliflozin (6.4% vs. 1.8%), while patients in the group 
treated using placebo were found to develop acute 
renal failure significantly more often (6.6% vs. 5.2%); 
significantly more frequent urinary tract infections in 
female patients in the placebo group were also observed 
(40.6% vs. 36.4%). Frequency of diabetic ketoacidosis 
did not exceed 0.1% and was similar in all groups.
In conclusion of their work the authors state that 
adding empagliflozin to current hypoglycaemic therapy 
reduces mortality due to cardiovascular causes and 
other causes in patients with type 2 diabetes with 
concomitant cardiovascular disease.
Commentary
The results of the EMPA-REG OUTCOME have 
shown that including empagliflozin in the standard 
treatment of patients with type 2 diabetes at high 
cardiovascular risk allows for a statistically significant 
38% reduction in the number of deaths due to cardio-
vascular causes. Empagliflozin is the first hypoglycaemic 
agent for which a protective effect against death was 
observed. Using the drug allows to save the life of 1 
patient per 39 treated (NNT — number needed to treat). 
Beneficial effect of empagliflozin occurred irrespectively 
of how well glycaemia was controlled. Despite the fact 
that the protocol of the trial allowed for intensification 
of hypoglycaemic therapy, HbA1c levels at the end of the 
observation were 8.16 in the placebo group and 7.81 
in the group treated using empagliflozin. This indicates 
that whether glycaemia is controlled or not is of less 
significance for achieved results. On the other hand, 
this also confirms that postulating more lenient criteria 
for glycaemia control in patients with CV diseases is 
valid [17]. The beneficial protective effect of empa-
gliflozin was already visible after only a few months 
of treatment, which means that it is highly difficult 
to point out the exact mechanism which causes the 
action protecting against premature death, especially 
since no significant reduction in the risk of myocardial 
infarction or non-fatal stroke has been observed. This 
may be due to the cardiological profile of patients, 
since in this case adequate hypotension (more than 
80% were taking drugs which block the RAAS) and 
hypolipidemic (75% were taking statin) therapies were 
being administered; 80% of patients were also taking 
aspirin. This confirms a direct effect of empagliflozin, 
supporting optimal cardiological treatment, on mor-
tality. The actual mechanism of this protective action 
remains an open question.
The following mechanisms are postulated [18]:
 — reduction in insulin resistance;
 — reduction in oxidative stress;
 — increase in levels of HDL cholesterol fractions and 
reduction in levels of triglycerides despite an in-
crease in LDL cholesterol levels;
 — reduction in uric acid levels;
 — reduction in albuminuria;
 — reduction in systolic blood pressure and arterial 
stiffness;
 — reduction in sympathetic activity.
This kind of influence of SGLT2 inhibitors as an 
added effect to other clinical features, namely reduc-
tion in glycaemia and body mass, was documented in 
numerous clinical and experimental trials [18].
Another interesting hypothesis explaining the car-
dioprotective effect of empagliflozin was presented by 
Ferranini et al. [19]. They postulate that under condi-
tions of mild, persistent ketonemia, which occur during 
Table 3. The EMPA-REG OUTCOME trial — results
Parameter HR (CI) P
Primary outcome 0.86 (0.74–0.99) P = 0.04
Secondary outcome 0.89 (0.78–1.01) P = 0.08
CV death 0.62 (0.49–0.77) P < 0.001
All cause death 0.68 (0.57–0.72) P < 0.001
Hospitalization for heart failure 0.65 (0.50–0.85) P = 0.002
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treatment using SGLT2 inhibitors, beta-hydroxybutyric 
acid is taken up by various organs, including the heart, 
resulting in oxidation of free fatty acids being displaced. 
This substrate selection increases the transduction of 
oxygen consumption into cell metabolism at the mito-
chondrial level. Furthermore, the hemoconcentration 
which follows administration of SGLT2 inhibitors in-
creases oxygen release to the tissues, thereby establish-
ing a strong synergy with the metabolic substrate shift. 
These cell mechanisms may cooperate with observed 
clinical effects (increased diuresis, reduced blood pres-
sure) to achieve the protective effect observed during 
the EMPA-REG OUTCOME trial.
Concerning hypoglycaemic agents, it was so far 
shown that including metformin in case of patients 
with newly diagnosed diabetes who are concomitantly 
overweight allowed to reduce the risk of myocardial 
infarction [20]. However, this effect was only observed 
in those patients, in whose case there was no necessity 
to include further hypoglycaemic agents during the 
trial. In turn, including pioglitazone in patients at high 
CV risk reduced the probability of CV complications, but 
was associated with increased risk of heart failure [21].
Results obtained during the EMPA-REG OUTCOME 
trial show decreased mortality and occurrence of other 
complications, at the cost of merely increasing fre-
quency of genital infections — a complication which 
is easily treatable and which did not cause the need 
to discontinue the therapy during the trial. The EMPA-
REG OUTCOME trial is a breakthrough in the treatment 
of type 2 diabetes, enabling the possibility to reduce 
mortality of patients with type 2 diabetes.
We await the results of other ongoing trials con-
cerning this class of drugs. These include, among oth-
ers, DECLARE, a trial of dapagliflozin, CANVAS, a trial 
of canagliflozin, and VERTIS, a  trial of ertugliflozin 
[22]. They will allow to assess whether the protective 
effect concerns the entire class of SGLT2 inhibitors or 
is specific only to empagliflozin.
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